drugset / Trial / NCT01063803
Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This open-label extension study will allow subjects who have completed either the 3242K1-2000-WW or 3242K1-2001-JA study to receive up to an additional 48 weeks of ATN-103 treatment and will provide data on the long-term safety and tolerability of ATN-103 in subjects with rheumatoid arthritis.
Timeline
- Start
- 2010-02
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OZORALIZUMAB | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | OZORALIZUMAB | Monoclonal antibody | 80 mg | Subcutaneous |